Ascendis ready for new hires after FDA approval

For a long time, Ascendis has been preparing for the approval of growth hormone Skytrofa, and the company can now execute launch and expansion plans.
Photo: Kevin Grønnemann/MedWatch
Photo: Kevin Grønnemann/MedWatch
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

Ascendis Pharma is chomping at the bit after securing a long-awaited approval for Transcon hGH, which will be marketed as Skytrofa. The company has already prepared launch plans to be initiated immediately.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading